Inhibition of TRPM3 by Primidone Provides a Potential Therapeutic Method for Adenomyosis Management
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s494981 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Zhixing Jin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215123, People's Republic of China. Hauptthemen laut MEDLINE: Adenomyosis, TRPM Cation Channels, Pyrimidinones. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
To test the expression profile of transient receptor potential channels (TRPs) in adenomyosis patients and evaluate the effects of primidone on tamoxifen-induced adenomyosis mice. Patients and Methods: This study included in vivo animal model and human tissue samples. Eutopic endometrium from adenomyosis patients (n=20) was collected and subjected to mRNA analysis of TRP channels. TRPA1, TRPV1 and TRPM3 in adenomyosis patients (n=50) and tamoxifen-induced adenomyosis mice (n=6) were examined by immunohistochemistry. From 10 weeks after birth, primidone (2 mg/kg/d) and atosiban (1 mg/kg/d) were given separately to adenomyotic mice by intraperitoneal injection for 3 weeks. The hotplate test was conducted once a week beginning at 10 weeks, and then uterine samples were harvested for HE staining and RNA-seq at 13 weeks.
Results
The mRNA expression of 15 TRPs was significantly increased in the proliferative phase of the adenomyotic endometrium. TRPV1, TRPM3 or TRPA1 staining levels were positively correlated with dysmenorrhea severity, menses amount and uterine size. In tamoxifen-induced adenomyosis mice, primidone had a significant effect on both the depth of myometrial infiltration and analgesia. Forty-seven DEGSSs were identifieSd after primidone treatment, and bioinformatics analysis predicted that they were enriched in the cell cycle and cell division.
Conclusion
The expression profile of TRP channels varies significantly in adenomyosis patients, and primidone may provide a potential therapeutic method for adenomyosis management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215123, People's Republic of China.
- Shanghai Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, People's Republic of China.
- Department of Pathology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215123, People's Republic of China.
ORCID-Profile: Zhixing Jin
Zitieren
APA
Jin, Z., Peng, Y., Zhang, H., He, X., Zhang, Y., Pan, X., Li, M., & Yang, Q. (2025). Inhibition of TRPM3 by Primidone Provides a Potential Therapeutic Method for Adenomyosis Management. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s494981
Vancouver
Jin Z, Peng Y, Zhang H, He X, Zhang Y, Pan X, et al. Inhibition of TRPM3 by Primidone Provides a Potential Therapeutic Method for Adenomyosis Management. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s494981
BibTeX
@article{Jin2025,
author = {Jin, Zhixing and Peng, Yaoming and Zhang, He and He, Xiaoping and Zhang, Yi and Pan, Xin and Li, Min and Yang, Qianqian},
title = {Inhibition of TRPM3 by Primidone Provides a Potential Therapeutic Method for Adenomyosis Management},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s494981}
}
EUVIMED